Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: A randomized, multicenter study of G-CSF starting on day+1 vs day+5 after autologous peripheral blood progenitor cell transplantation
Author: de Azevedo, AM
Nucci, M
Maiolino, A
Vigorito, AC
Simoes, BP
Aranha, FJP
Tabak, DG
Voltarelli, J
de Souza, C
Abstract: In order to assess the effect of delaying G-CSF administration after autologous peripheral blood progenitor cell (PBPC) transplantation on the duration of neutropenia, 87 patients were randomized to receive G-CSF 5 mug/kg/day starting on day +1 (n = 45) or +5 (n = 42) following PBPC transplantation, until recovery of the neutrophils. The duration of neutropenia (<0.5 x 10(9)/1) was shorter in the day +1 group (7 vs 8 days; P = 0.02), especially in patients receiving melphalan 200 mg/m(2) and CD34(+) cell doses >3.0 X 10(6)/kg. These patients had a later onset of neutropenia after transplant. There were no differences in time to neutrophil and platelet engraftment, or in the incidence of fever and documentation of infection. Although the duration of antibiotic therapy (7 vs 10.5 days; P = 0.01) and time to hospital discharge (13 vs 15 days; P = 0.02) were shorter in the day +1 group, these differences could not be predicted by the day of G-CSF initiation in multivariate analysis. Starting G-CSF on day +1 does not result in faster neutrophil engraftment but in later onset and consequently, slightly shorter duration of neutropenia in patients who receive melphalan 200 mg/m2 and CD34(+) cell doses >3.0 x 10(6)/kg.
Subject: G-CSF
bone marrow transplants
clinical trial
Country: Inglaterra
Editor: Nature Publishing Group
Citation: Bone Marrow Transplantation. Nature Publishing Group, v. 29, n. 9, n. 745, n. 751, 2002.
Rights: fechado
Identifier DOI: 10.1038/sj/bmt/1703538
Date Issue: 2002
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000176059600005.pdf3.08 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.